Amgevita (Adalimumab)

Amgevita (adalimumab) is a biologic medicine that helps the pain and swelling of arthritis.

Amgevita is used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Inflammatory Arthritis, Psoriasis, Crohn's Disease, Hidradentitis, Iritis, and other diseases.

Amgevita works by blocking Tumor Necrosis Factor (TNF), a type of signalling protein (called a cytokine), that is involved in systemic inflammation. Amgevita belongs to a class of similar medications called Anti-Tumor Necrosis Factor agents.

Amgevita may be prescribed in combination with other rheumatology medications like methotrexate.

Biosimilar

Amgevita is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that is designed to be identical to an existing biologic medication, but is created using a different process.

Amgevita is a biosimilar of Humira. Both medications are known by the same generic name: adalimumab. Biosimilars are often cheaper than the original medication.

Taking Amgevita

Amgevita is available as a subcutaneous (under the skin) injection in one of two forms that can be taken at home: as a pre-filled syringe, and as an autoinjector (pen).

Amgevita usually takes about 2 weeks before patients start to feel its effects. It may take 12 weeks to feel the effect of this medicine.

The manufacturer of Amgevita offers a support program to Canadian patients that are prescribed the medication:

Patient support program enrolment forms

Important Tests and Risks

Science

Safety

Resource(s)

Amgevita Quick Reference Guide

Drug Identification Number (DIN)

02459299

02459310

02459302